Autres langues Asymchem Laboratories (Tianjin) Co., Ltd. OTC Markets

Actions

ASLT.Y

US04651E1038

Produits pharmaceutiques

Autres langues

06:24	Asymchem Laboratories to Subscribe for Subsidiary's New Shares for 1.05 Billion Yuan; Shares Up 6%
27/07	AsymBio, Subsidiary of Asymchem Group Kicks Off Construction of Fengxian R&D Building
11/06	Asymchem Laboratories Co., Ltd. Approves Final Profit Distribution Plan to Be Implemented (A Shares) for 2025, Payable on June 26, 2026
27/05	AsymBio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates
27/05	AsymBio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates
27/05	Asymbio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates
20/05	Citigroup's long position in H shares of Asymchem Laboratories (Tianjin) decreases to 4.99% on May 14 from 5.66%, HKEX filing says
15/05	Asymchem Laboratories Co., Ltd. Recommends Final Dividend for the Year Ended 31 December 2025, Payable on 24 July 2026
13/05	Citigroup's long position in H-shares of Asymchem Laboratories (Tianjin) decreases to 5.36% on May 7, HKEX says
04/05	JPMorgan Chase's long position in H-shares of Asymchem Laboratories (Tianjin) decreases to 7.64% on Apr 28 from 8.18%, HKEX filing shows
28/04	Asymchem Laboratories' Profit Falls 6.8% in Q1; Shares Rise 8%
27/04	Asymchem Laboratories Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
27/04	Asymchem Laboratories (Tianjin) Q1 net profit down 6.8% Y/Y
21/04	Asymchem Laboratories Profit Rises 19% in 2025
14/04	Asymchem Unveils Fully Integrated TIDES Commercial Supply Matrix
30/03	Asymchem Laboratories (Tianjin) 2025 net profit up 19.4% Y/Y
30/03	Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
30/03	Asymchem Laboratories Co., Ltd. announces Annual dividend, payable on June 26, 2026
09/03	AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities
09/03	AsymBio Completes Dual-Site One-Center Network With Fengxian Commercial Manufacturing Site Operational
25/02	Citigroup's long position in H-shares of Asymchem Laboratories (Tianjin) increases to 11.67% on Feb 19 from 9.34%, HKEX filing shows
22/12	Asymchem Laboratories Cuts Buyback Price Under 2025 Share Scheme; Shares
08/12	Asymbio Commences Commercial Operations At Fengxian Base, Strengthening Global Biopharmaceutical Cdmo Capabilities
30/10/25	Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025
30/10/25	Asymchem Laboratories (Tianjin) posts qtrly profit attributable RMB182.8 million